Skip to main content

Table 1 Demographics and baseline characteristics

From: Pharmacokinetics of surotomycin from phase 1 single and multiple ascending dose studies in healthy volunteers

Characteristic Single ascending dose Multiple ascending dose
500 mg (n = 8) 1000 mg (n = 8) 2000 mg (n = 8) 4000 mg (n = 8) Overall (n = 32) Placebo (n = 8) 250 mg BID (n = 8) 500 mg BID (n = 8) 1000 mg BID (n = 8) Overall (n = 24) Placebo (n = 6)
Age (years)
 Mean ± SD 47.6 ± 14.94 42.0 ± 20.47 41.5 ± 15.58 40.6 ± 18.55 42.9 ± 16.89 28.3 ± 13.25 43.3 ± 10.43 47.9 ± 14.93 51.8 ± 13.51 47.6 ± 13.00 48.8 ± 20.91
 Median 47.50 37.00 41.50 35.50 43.00 25.00 47.00 53.00 50.50 50.50 50.50
 Min, max 23.0, 66.0 19.0, 67.0 21.0, 62.0 21.0, 69.0 19.0, 69.0 18.0, 58.0 27.0, 53.0 20.0, 69.0 29.0, 70.0 20.0, 70.0 25.0, 70.0
Sex, n (%)
 Male 4 (50.0) 4 (50.0) 4 (50.0) 4 (50.0) 16 (50.0) 4 (50.0) 4 (50.0) 4 (50.0) 4 (50.0) 12 (50.0) 3 (50.0)
Race, n (%)
 Asian 0 0 1 (12.5) 2 (25.0) 3 (9.4) 0 1 (12.5) 0 0 1 (4.2) 2 (33.3)
 Black 2 (25.0) 2 (25.0) 1 (12.5) 0 5 (15.6) 2 (25.0) 1 (12.5) 2 (25.0) 2 (25.0) 5 (20.8) 1 (16.7)
 White 6 (75.0) 5 (62.5) 6 (75.0) 6 (75.0) 23 (71.9) 6 (75.0) 6 (75.0) 6 (75.0) 6 (75.0) 18 (75.0) 3 (50.0)
 Other 0 1 (12.5) 0 0 1 (3.1) 0 0 0 0 0 0
BMI (kg/m2)
 Mean ± SD 26.2 ± 4.11 24.0 ± 4.11 23.0 ± 2.83 28.7 ± 4.73 25.5 ± 4.41 23.9 ± 4.02 27.6 ± 1.28 27.8 ± 4.37 26.8 ± 3.15 27.4 ± 3.08 25.8 ± 4.48
 Median 24.29 25.31 22.37 27.51 25.50 22.17 27.70 27.80 25.90 27.40 25.55
 Min, max 22.7, 32.4 17.9, 28.3 19.8, 27.6 22.0, 25.3 17.9, 35.3 20.2, 32.2 25.5, 29.7 21.6, 35.2 23.6, 32.7 21.6, 35.2 19.8, 31.7
  1. BID Twice daily, BMI Body mass index, SD Standard deviation